H.C. Wainwright Upgrades Prime Medicine (PRME) to "Buy" Following Key Clinical Advancements
Money

H.C. Wainwright Upgrades Prime Medicine (PRME) to "Buy" Following Key Clinical Advancements

authorBy Chika Uwazie
DateJul 05, 2026
Read Time2 min

H.C. Wainwright has elevated its rating for Prime Medicine (PRME) to "Buy," indicating strong confidence in the company's future. This positive shift is primarily driven by recent breakthroughs in Prime Medicine's gene-editing programs, which are expected to unlock substantial growth potential. These developments highlight the biotechnology firm's capacity to innovate and advance its therapeutic solutions, attracting increased attention from market analysts.

On June 29, 2026, H.C. Wainwright announced its decision to upgrade Prime Medicine (PRME) to a "Buy" rating, accompanied by a price target of $8. This move followed the New Zealand Medicines and Medical Devices Safety Authority's approval of the clinical trial application for PM577a, Prime Medicine's experimental treatment for Wilson's disease. The firm emphasized that this regulatory clearance significantly reduces risk and marks the first clinical authorization for an in vivo prime editing therapy developed by Prime Medicine. The company had initially announced this crucial clearance on June 18, 2026, paving the way for a global Phase 1/2 study of PM577a in both adults and adolescents afflicted with Wilson Disease. Allan Reine, the CEO, hailed this achievement as a pivotal moment, underscoring PM577a's potential to genetically correct the disease with a single treatment. Chief Medical Officer Mohammed Asmal further noted that the trial design is based on the company's extensive preclinical research, with initial proof-of-concept data anticipated in 2027.

Adding to Prime Medicine's recent successes, on June 22, 2026, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. This stem cell therapy targets p47phox-deficient chronic granulomatous disease (CGD) and received the designation based on promising Phase 1/2 clinical data published in The New England Journal of Medicine. CEO Allan Reine stated that this designation facilitates closer engagement with the FDA, moving the company closer to a future Biologics License Application. Prime Medicine is a biotechnology firm dedicated to developing genetic medicines through advanced gene editing technology, aiming to address a broad spectrum of human diseases.

Prime Medicine's recent clinical and regulatory achievements underscore its strong position in the biotechnology landscape. The company's innovative gene-editing platform and pipeline advancements suggest a promising trajectory for addressing complex diseases and delivering significant value to patients and investors alike.

More Articles
Money
Forager Capital Management's Acquisition Proposal for Repay Holdings
Forager Capital Management has submitted an unsolicited, non-binding proposal to acquire all outstanding shares of Repay Holdings Corporation for $5.25 per share in cash. Repay's Board of Directors is currently evaluating this offer with the assistance of legal and financial advisors, advising shareholders to take no immediate action. Repay Holdings is a payment technology company specializing in integrated electronic payment solutions.
By T. Harv EkerJul 05, 2026
Money
Netskope's Market Outlook: KeyBanc's "Overweight" Rating and a $15 Price Target Explained
KeyBanc has reiterated an "Overweight" rating on Netskope (NTSK) with a $15 price target, despite lowering it from $15. This decision follows a survey highlighting increased AI spending, positioning Netskope as a strong player in the security, data, and infrastructure sectors. TD Cowen also maintains a "Buy" rating with a $19 target, citing robust industry trends and expected free cash flow growth. The stock's current valuation is considered compelling, even with a year-to-date decline of over 30%.
By Vicki RobinJul 05, 2026
Money
Cantor Fitzgerald Sets Ambitious $700 Price Target for AMD, Citing Dominance in AI Chip Race
Cantor Fitzgerald analyst C.J. Muse has significantly raised his price target for Advanced Micro Devices (AMD) to $700, positioning it as the top pick in the computing sector, ahead of Nvidia and Broadcom. This bold prediction comes as AMD demonstrates strong momentum in the AI chip market, despite recent stock fluctuations and broader market skepticism regarding its valuation. The analyst's confidence is rooted in AMD's robust data center growth and the increasing demand for its high-performance chips, particularly its EPYC Venice server processors and AI accelerators.
By Scott PapeJul 05, 2026
Money
Hedge Fund Divests Significant Stake in Establishment Labs Amidst Strong Performance
JW Asset Management, a hedge fund, recently sold 90,533 shares of Establishment Labs Holdings Inc. for approximately $6.64 million. Despite this substantial divestment, the fund retains a significant holding, indicating continued bullish sentiment. This transaction occurred as Establishment Labs experienced robust revenue growth and inclusion in the Russell 2000 Index, driving its stock to a 52-week high.
By Ramit SethiJul 05, 2026
Money
Petco's Strategic Revival: A Promising Prospect for Value Investors
Petco Health and Wellness Company Inc. (NASDAQ: WOOF) has demonstrated a robust financial rebound in FQ1 2026, driven by its "Reach for the Sky" strategy. The company reported positive comparable sales growth and improved profitability, making it an attractive value penny stock according to hedge funds. With reduced debt and a maintained full-year outlook, Petco aims to strengthen its market position in pet products and services.
By JL CollinsJul 05, 2026